“The company continues to execute in a challenging environment, delivering organic revenue above our guidance,” CEO Geoff Martha said in Tuesday’s report. “As we look ahead, our supply chain is improving, we have several near-term pipeline catalysts approaching, and we are confident in our ability to accelerate growth.”
The above is an extract from an article in Fierce Pharma relative to Medtronics. Link to article below -
https://www.fiercebiotech.com/medtech/medtronic-still-eyeing-modest-year-over-year-growth-fiscal-2023-kicks-slipping-revenues?utm_source=email&utm_medium=email&utm_campaign=LS-NL-FiercePharma+Tracker&oly_enc_id=9563F4064234D3D
I am just wondering if "the several near-term pipeline catalysts" include a deal with Anteris.
Ann: Third Conversion of Securities - Mercer, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.20 |
Change
0.290(4.91%) |
Mkt cap ! $96.09M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.20 | $5.91 | $13.21K | 2.194K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1940 | $6.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.37 | 1687 | 2 |
View Market Depth
| Last trade - 11.06am 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |